Ketamine vs electroconvulsive therapy for treatment-resistant depression — evidence strength, cognitive side effects, speed, and cost compared.
Ketamine and electroconvulsive therapy (ECT) are both used for depression that has not responded to standard antidepressants, including some of the most severe cases. They are also very different treatments — different mechanisms, different settings, and different side-effect profiles. This guide compares them side by side so you can bring an informed set of questions to your psychiatrist. It does not declare a winner; that decision belongs to you and your care team.
Here is a fast, side-by-side look at the main differences. Details and sources follow below.
| Factor | Ketamine | ECT (electroconvulsive therapy) |
|---|---|---|
| How it works | An NMDA-receptor antagonist given as a nasal spray (Spravato), IV, IM, or oral lozenge. No anesthesia or seizure involved. | A brief, controlled seizure is induced under general anesthesia using electrical stimulation of the brain. |
| Setting | Outpatient clinic, certified office, or supervised telehealth. No anesthesia team required. | Hospital or specialized outpatient suite with an anesthesiologist and full monitoring team present. |
| FDA / regulatory status | Esketamine (Spravato) is FDA-approved for treatment-resistant depression. Ketamine is a Schedule III controlled substance; IV/IM use for depression is off-label. | ECT devices are FDA-regulated medical devices. ECT itself is not a scheduled drug and has been an accepted psychiatric treatment for decades. |
| Typical course | Spravato: twice weekly for the first month, then tapering. IV: often around 6 infusions over 2–3 weeks, then maintenance. | Usually 6–12 sessions over 2–4 weeks (2–3 sessions per week), sometimes followed by maintenance sessions. |
| Speed of response | Often fast — many people feel relief within hours to a few days. | Typically several sessions in before improvement is clear, though it can still act faster than standard antidepressants. |
| Evidence strength | Strong evidence for short-term antidepressant effect; a newer treatment with a shorter track record than ECT. | The longest and deepest evidence base of any treatment for severe depression, generally considered the most effective option for the most severe or psychotic depression. |
| Cognitive / memory effects | Short-term dissociation during dosing. Long-term memory effects are not a well-established concern at therapeutic doses. | Memory-related side effects, especially short-term memory loss around the time of treatment, are a well-established and significant consideration. |
| Invasiveness | No anesthesia, no induced seizure. Considered less invasive. | Requires general anesthesia and a muscle relaxant for each session, plus a full medical team. |
Ketamine acts on the brain's glutamate system, blocking the NMDA receptor. This is thought to trigger fast changes in mood-related brain connections, which is part of why relief can come quickly. It is given as a nasal spray (Spravato), IV or IM infusion, or an at-home oral lozenge under telehealth supervision. No anesthesia or induced seizure is involved. For the full picture, see our ketamine therapy guide.
ECT induces a brief, controlled seizure using electrical stimulation of the brain, done under general anesthesia with a muscle relaxant so the body does not convulse. A psychiatrist and anesthesia team manage the session, which typically lasts a few minutes, plus recovery time. Sessions happen in a hospital or a specialized outpatient suite with full monitoring.
ECT has been used in psychiatry for decades and remains one of the most closely studied treatments for severe depression, including cases with psychotic features or high suicide risk where a fast, reliable response is critical.
This is where the two treatments differ most. ECT has the longest track record of any depression treatment discussed on this site and is generally regarded by major psychiatric reviews as the most effective option available for the most severe and treatment-resistant depression, including depression with psychotic features. Its evidence base spans decades of use and study.
Ketamine's evidence base is real and growing but newer. Clinical trials, including the Phase 3 trials behind Spravato's FDA approval, show a strong short-term antidepressant effect. What is still being established is how ketamine's long-term effectiveness and durability compare to ECT's longer track record, particularly for the most severe cases. Neither fact should be read as "ketamine is unproven" or "ECT is outdated" — both are real, evidence-backed options with different strengths.
This is often the deciding factor for patients. ECT's memory-related side effects — particularly short-term memory loss around the time of treatment, and less commonly longer gaps in memory for events before treatment — are well documented and a significant part of the conversation before starting ECT. For some patients these effects are temporary; for others they can be more persistent, and this varies by individual and by the specific ECT technique used.
Ketamine's most prominent cognitive effect is the dissociation felt during the dosing window itself, which resolves as the drug wears off. Long-term memory loss is not considered a well-established concern at the doses used for depression treatment, though frequent, high-dose use over time carries its own separate risks. See our ketamine side effects guide for the full list of short-term effects and the long-term bladder risk tied to heavy, frequent use.
Ketamine is often the faster of the two to produce an initial response, with some patients reporting relief within hours to a few days of a first dose — part of why it is used in situations where speed matters, such as severe depression with active suicidal thoughts. ECT typically takes several sessions before a clear improvement emerges, though it can still act faster than standard oral antidepressants, which often take weeks.
Access and legal status differ meaningfully between the two:
Neither treatment is a first-line option — both are typically considered after standard antidepressants and often after other options like TMS have been tried, though ECT is sometimes moved up sooner for the most severe or life-threatening presentations. General patterns reported in the literature and clinical practice:
Compare ketamine to another non-invasive option in our ketamine vs TMS guide, or to standard antidepressant medications in our ketamine vs antidepressants guide.
There is no universal answer to "which is better, ketamine or ECT." ECT carries the deeper evidence base and is generally viewed as the more effective option for the most severe depression; ketamine offers faster relief for many patients with a less invasive process and a different side-effect profile. Severity, prior treatment history, medical eligibility for anesthesia, and personal tolerance for cognitive side effects all factor into the decision. This is a conversation to have directly with a psychiatrist familiar with your full history — not a choice to make from a comparison chart alone.
Whichever path you take, pairing it with follow-up therapy improves outcomes. See our integration therapy guide for what that support can look like.
There is no single answer. ECT has the longest evidence base of any depression treatment and is generally considered the most effective option for the most severe or psychotic depression. Ketamine offers faster relief for many patients with a less invasive process. Which is more appropriate depends on severity, prior treatment history, and a psychiatrist's assessment.
No, not in the same well-established way. ECT's memory-related side effects, particularly short-term memory loss around the time of treatment, are a significant and well-documented consideration. Ketamine's main cognitive effect is dissociation during the dosing window itself, which resolves as the drug wears off; long-term memory loss is not considered a well-established concern at therapeutic depression doses.
No. Ketamine is given as a nasal spray, IV or IM infusion, or an oral lozenge without general anesthesia. ECT requires general anesthesia and a muscle relaxant for every session, plus an anesthesia team, which makes it a more invasive procedure than ketamine.
ECT courses typically run 6 to 12 sessions over 2 to 4 weeks. A typical IV ketamine course runs around 6 infusions over 2 to 3 weeks, while Spravato follows a twice-weekly schedule for the first month before tapering. Both may continue with maintenance sessions afterward.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.